الفهرس 
Chronic hepatitis C infectionOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
Objective : Impact of obesity on SVR to antiviral therapy in CHC patients was heavily studied as regard interferon based regimens. In the current era of highly effective direct-acting antivi¬ral therapies for chronic HCV infection, estimation of factors that affect response to DAAs is still a critical issue despite high efficacy of these drugs, as the ability to eradi¬cate HCV will not only improve short and long term clinical outcome of HCV-related liver disease, but will likely impact on the incidence and prevalence of HCV-related extrahepatic diseases. So the aim of our study is the assessment of the impact of obesity on SVR to sofosbuvir based regimens in CHC patients.
Methods : We studied 200 chronic hepatitis C patients by divided them into 2 groups (obese and non obese) each group included 100 patients. Each group was subdivided into 3 groups and they received sofosbuvir based regimens as follow,
group A: 35 patients received sofosbuvir (400 mg) plus daclatasvir (60 mg) per day for 12 weeks.
group B: 35 patients received sofosbuvir (400 mg) plus simeprevir (150 mg) per day for 12 weeks.
group C: 30 patients received sofosbuvir (400 mg) plus ledipasvir (90 mg) plus weight-based ribavirin (1000-1200 mg) per day for 12 weeks.
Results : There is no statistically significant difference between obese and non obese chronic hepatitis C patients received sofosbuvir based regimens regarding sustained virologic response.